Laupheim, Germany, July 25, 2012 / B3C newswire / - Rentschler, a leading CMO for the development and production of biopharmaceuticals, has hosted its second Laupheimer Zelltage conference with the theme ‘Bioprocess light’ on June 11 and 12, 2012 in Laupheim, Germany. Over 190 leading scientists from industry and academia shared their ideas on strategies to facilitate processes and implement lean biomanufacturing principles aimed at generating superior, economical, robust, and competitive processes. Download the conference report and the abstracts of the presentations.
The symposium program consisted of three sessions focusing on New Targets for Animal Cell Technology’, ‘The Efficient Process’ and ‘Cutting-Edge Technologies’. The lectures included a wide range of topics such as predicting cell line productivity, the advantage of pre-developed producer cells, key components of chemically defined cell culture media, and novel disposable and process intensification technologies. Thus, these presentations helped forge a link between cell line development and production.
“Contract manufacturers are pushed towards continuously improving processes and the two-day event was full of inspiring lectures and discussions on new strategies and technologies to enhance quality, efficiency and process robustness,” said Prof. Roland Wagner, Senior Vice President Development at Rentschler. “Besides process optimization, there is a clearly visible trend towards flexible multiproduct manufacturing facilities to reduce the cost of goods, significantly lower initial capital investments, and increase plant capacity.”
The Laupheimer Zelltage conferences on industrial cell culture technology are carried out in a biennial rhythm. The next conference in June 2014 will be on Advanced Therapy Medicinal Products and is entitled “Processes for ATMPs’.
About Rentschler
Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.
Contact for more information about the symposium:
Prof. Dr. Roland Wagner
Senior Vice President Development
Rentschler Biotechnologie GmbH
Phone: +49 7392 701-857
roland.wagner@rentschler.de
Media Contact:
Friederike Braun
Director Marketing
Rentschler Biotechnologie GmbH
Phone: +49 7392 701-478
friederike.braun@rentschler.de
